SVA vs. MDNA, ONC, TH, MBX, HBP, FRX, EDT, HLS, CRDL, and HTL
Should you be buying Sernova stock or one of its competitors? The main competitors of Sernova include Medicenna Therapeutics (MDNA), Oncolytics Biotech (ONC), Theratechnologies (TH), Microbix Biosystems (MBX), Helix BioPharma (HBP), Fennec Pharmaceuticals (FRX), Spectral Medical (EDT), HLS Therapeutics (HLS), Cardiol Therapeutics (CRDL), and Hamilton Thorne (HTL). These companies are all part of the "medical" sector.
Medicenna Therapeutics (TSE:MDNA) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.
7.9% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Sernova shares are owned by institutional investors. 23.7% of Medicenna Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Medicenna Therapeutics received 80 more outperform votes than Sernova when rated by MarketBeat users. However, 88.89% of users gave Sernova an outperform vote while only 68.22% of users gave Medicenna Therapeutics an outperform vote.
In the previous week, Medicenna Therapeutics had 2 more articles in the media than Sernova. MarketBeat recorded 3 mentions for Medicenna Therapeutics and 1 mentions for Sernova. Medicenna Therapeutics' average media sentiment score of 0.84 beat Sernova's score of 0.54 indicating that Sernova is being referred to more favorably in the news media.
Sernova has a consensus price target of C$1.50, suggesting a potential upside of 240.91%. Given Medicenna Therapeutics' higher probable upside, analysts clearly believe Sernova is more favorable than Medicenna Therapeutics.
Sernova's return on equity of -59.47% beat Medicenna Therapeutics' return on equity.
Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.
Medicenna Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
Summary
Medicenna Therapeutics beats Sernova on 7 of the 13 factors compared between the two stocks.
Get Sernova News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
